Matinas BioPharma - MTNB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 440.54 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.56
▼ -0.015 (-2.63%)

This chart shows the closing price for MTNB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Matinas BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MTNB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MTNB

Analyst Price Target is $3.00
▲ +440.54% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Matinas BioPharma in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 440.54% upside from the last price of $0.56.

This chart shows the closing price for MTNB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Matinas BioPharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/13/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/12/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/23/2022AegisReiterated RatingBuy
3/9/2022HC WainwrightReiterated RatingBuy$3.00
9/14/2021HC WainwrightReiterated RatingBuy$3.00
5/11/2021Piper SandlerDowngradeOverweight ➝ Neutral
3/30/2021HC WainwrightReiterated RatingBuy$4.00 ➝ $3.00
2/15/2021AegisReiterated RatingBuy
1/29/2021Maxim GroupReiterated RatingBuy$3.00
1/4/2021Piper SandlerBoost TargetOverweight$1.80 ➝ $4.00
11/6/2020Maxim GroupInitiated CoverageBuy$3.00
8/13/2020AegisBoost TargetBuy$3.25 ➝ $3.50
8/11/2020HC WainwrightReiterated RatingBuy$4.00
6/2/2020AegisReiterated RatingBuy
5/23/2020Maxim GroupInitiated CoverageBuy$3.00
5/13/2020Maxim GroupReiterated RatingBuy
4/1/2020Maxim GroupInitiated CoverageBuy$3.00
3/6/2020Maxim GroupReiterated RatingBuy
1/26/2020Piper SandlerInitiated CoverageOverweight$3.00
1/23/2020SunTrust BanksInitiated CoverageBuy$3.00
1/9/2020AegisInitiated CoverageBuy$3.50
12/20/2019HC WainwrightReiterated RatingBuy$4.00
9/26/2019Maxim GroupReiterated RatingBuy$3.00
8/14/2019HC WainwrightReiterated RatingBuy$4.00
6/26/2019HC WainwrightReiterated RatingBuy
6/26/2019HC WainwrightInitiated CoverageBuy ➝ Buy$4.00
5/17/2019BTIG ResearchInitiated CoverageBuy$5.00
5/16/2019Maxim GroupReiterated RatingBuy$5.00
2/11/2019Roth CapitalReiterated RatingBuy
2/11/2019Roth CapitalInitiated CoverageBuy$4.75
11/12/2018Maxim GroupBoost TargetBuy ➝ Buy$2.00 ➝ $5.00
8/13/2018Maxim GroupLower TargetBuy ➝ Buy$3.00 ➝ $2.00
7/10/2018Maxim GroupLower TargetBuy ➝ Buy$4.00 ➝ $3.00
5/10/2018Maxim GroupSet TargetBuy$4.00
4/23/2018Maxim GroupSet TargetBuy$4.00
3/19/2018Maxim GroupSet TargetBuy$6.00
(Data available from 12/7/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2022
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/8/2022
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
11/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Matinas BioPharma logo
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Read More

Today's Range

Now: $0.56
Low: $0.54
High: $0.59

50 Day Range

MA: N/A

52 Week Range

Now: $0.56
Low: $0.49
High: $1.16

Volume

16,914 shs

Average Volume

279,888 shs

Market Capitalization

$120.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.91

Frequently Asked Questions

What sell-side analysts currently cover shares of Matinas BioPharma?

The following Wall Street analysts have issued stock ratings on Matinas BioPharma in the last year: Aegis, and HC Wainwright.
View the latest analyst ratings for MTNB.

What is the current price target for Matinas BioPharma?

1 Wall Street analysts have set twelve-month price targets for Matinas BioPharma in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 440.5%. HC Wainwright has the highest price target set, predicting MTNB will reach $3.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $3.00 for Matinas BioPharma in the next year.
View the latest price targets for MTNB.

What is the current consensus analyst rating for Matinas BioPharma?

Matinas BioPharma currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MTNB will outperform the market and that investors should add to their positions of Matinas BioPharma.
View the latest ratings for MTNB.

What other companies compete with Matinas BioPharma?

How do I contact Matinas BioPharma's investor relations team?

Matinas BioPharma's physical mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company's listed phone number is (908) 443-1860 and its investor relations email address is [email protected] The official website for Matinas BioPharma is www.matinasbiopharma.com. Learn More about contacing Matinas BioPharma investor relations.